Breaking News Instant updates and real-time market news.

EXEL

Exelixis

$20.40

-0.62 (-2.95%)

, IPSEY

Ipsen

$0.00

(0.00%)

05:29
05/17/18
05/17
05:29
05/17/18
05:29

Exelixis partner Ipsen announces EC approval of Cabometyx

Exelixis (EXEL) announced that its partner Ipsen (IPSEY) received approval from the European Commission, or EC, for Cabometyx 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk advanced renal cell carcinoma, or RCC, in the European Union. Under the terms of the Collaboration and License Agreement with Ipsen, Exelixis will receive a milestone payment of $50 million for the EC approval, of which approximately $46 million was recognized as collaboration revenue in the first quarter of 2018. The payment will be made by Ipsen within the next 70 days.

EXEL

Exelixis

$20.40

-0.62 (-2.95%)

IPSEY

Ipsen

$0.00

(0.00%)

  • 21

    May

  • 12

    Jun

EXEL Exelixis
$20.40

-0.62 (-2.95%)

04/10/18
RBCM
04/10/18
NO CHANGE
RBCM
Top Pick
Exelixis selloff yesterday a buying opportunity, says RBC Capital
RBC Capital analyst Kennen MacKay attributes yesterday's late-date weakness in shares of Exelixis (EXEL) to the clinicaltrials.gov update for Roche's (RHHBY) first-line metastatic colorectal cancer maintenance study indicating that recruitment has been suspended. The study is assessing "Cotezo," a combination of Exelixis/Roche's Cotellic and Roche's Tecentriq. The analyst says his correspondence with Exelixis management highlights that this is a temporary halt on recruitment only. MacKay recommends buying Exelixis on the weakness and remains bullish on the IMblaze370 trial.
04/11/18
WBLR
04/11/18
NO CHANGE
WBLR
Outperform
William Blair an 'aggressive' buyer of Exelixis after 28% pullback
William Blair analyst Andy Hsieh says he's an "aggressive" buyer of Exelixis with the stock down 28% since the Q4 earnings call on February 28. The previously announced Merck-Eisai collaboration agreement to jointly develop and commercialize Lenvima could serve as a comp to Exelixis's cabozantinib franchise, Hsieh tells investors in a research note. Eisai ascribes a value of roughly $7.9B for the Lenvima franchise, which equates to $26.66 per share for Exelixis, the analyst writes. With Exelixis trading at $6.3B in market cap or $5.8B in enterprise value, the current valuation does not account for the full potential of the cabozantinib franchise and does not include Cotellic, which is in three Phase III studies and being investigated in four oncology indications, Hsieh argues. He keeps an Outperform rating on the shares and believes the Merck-Eisai Deal highlights a "significant valuation disconnect."
05/10/18
STFL
05/10/18
NO CHANGE
STFL
Hold
Exelixis pullback may create interesting entry point, says Stifel
After Exelixis (EXEL) and partner Roche (RHHBY) announced the Phase 3 IMblaze370 trial did not achieve statistical-significance on the primary efficacy endpoint evaluating the ability of a combination of a MEK inhibitor and anti-PD-L1 to improve overall survival in patients with microsatellite stable metastatic colorectal cancer, Stifel analyst Stephen Willey said he believes attrition in Exelixis shares might create an interesting entry point. The failure of IMblaze370 removes some of Exelixis' longer-term optionality and he expects topics of RCC growth/competition, label expansion, and longer-term cabozantinib exclusivity to remain core to the story going forward, said Willey who has a Hold rating on the stock. Array BioPharma (ARRY) also has Phase 1/2 development collaborations in place with both Bristol-Myers (BMY) and Merck (MRK) evaluating the MEK/PD-1 hypothesis in earlier-lines of MSS mCRC, noted Willey, who said he would "be opportunistic" on any weakness in its shares. He maintains a Buy rating on Array, which is down 5% in pre-market trading.
05/10/18
PIPR
05/10/18
NO CHANGE
Target $29
PIPR
Overweight
Exelixis price target lowered to $29 from $33 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target on Exelixis (EXEL) to $29 from $33 after partner Roche (RHHBY) reported the Phase 3 IMblaze370 trial in microsatellite stable colorectal cancer patients did not meet its overall survival primary endpoint. However, the data do not impact two ongoing Phase 3 trials of cobimetinib and Tecentriq in BRAF-mutant melanoma, said Tenthoff, who keeps an Overweight rating on Exelixis shares.
IPSEY Ipsen
$0.00

(0.00%)

09/19/17
SOCG
09/19/17
UPGRADE
SOCG
Buy
Ipsen upgraded to Buy from Hold at Societe Generale
Societe Generale analyst Delphine Le Louet upgraded Ipsen to Buy with a price target of EUR 126.

TODAY'S FREE FLY STORIES

COST

Costco

$227.35

1.68 (0.74%)

07:26
08/21/18
08/21
07:26
08/21/18
07:26
Recommendations
Costco analyst commentary  »

Costco price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Oct

LB

L Brands

$33.07

0.53 (1.63%)

07:26
08/21/18
08/21
07:26
08/21/18
07:26
Recommendations
L Brands analyst commentary  »

L Brands price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

MGM

MGM Resorts

$28.59

0.035 (0.12%)

, CZR

Caesars

$10.05

0.05 (0.50%)

07:25
08/21/18
08/21
07:25
08/21/18
07:25
Recommendations
MGM Resorts, Caesars analyst commentary  »

Room survey suggests…

MGM

MGM Resorts

$28.59

0.035 (0.12%)

CZR

Caesars

$10.05

0.05 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$225.37

2.76 (1.24%)

07:24
08/21/18
08/21
07:24
08/21/18
07:24
Initiation
Lennox initiated  »

Lennox initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

HCSG

Healthcare Services

$41.33

0.11 (0.27%)

07:23
08/21/18
08/21
07:23
08/21/18
07:23
Conference/Events
Healthcare Services management to meet with Benchmark »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 29

    Aug

GTT

GTT Communications

$38.30

-0.7 (-1.79%)

07:23
08/21/18
08/21
07:23
08/21/18
07:23
Recommendations
GTT Communications analyst commentary  »

GTT Communications should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOE

Ferro

$21.23

-0.06 (-0.28%)

07:22
08/21/18
08/21
07:22
08/21/18
07:22
Conference/Events
Ferro management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 11

    Sep

TSS

TSYS

$94.88

-0.01 (-0.01%)

07:21
08/21/18
08/21
07:21
08/21/18
07:21
Recommendations
TSYS analyst commentary  »

TSYS price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

  • 17

    Sep

  • 06

    Nov

FITB

Fifth Third

$29.83

0.145 (0.49%)

07:21
08/21/18
08/21
07:21
08/21/18
07:21
Conference/Events
Fifth Third management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 23

    Oct

YRCW

YRC Worldwide

$9.11

0.11 (1.22%)

07:21
08/21/18
08/21
07:21
08/21/18
07:21
Conference/Events
YRC Worldwide management to meet with Deutsche Bank »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 06

    Nov

MDT

Medtronic

$90.06

-0.54 (-0.60%)

07:20
08/21/18
08/21
07:20
08/21/18
07:20
Hot Stocks
Breaking Hot Stocks news story on Medtronic »

Medtronic up 4.4% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 23

    Aug

  • 05

    Sep

  • 12

    Sep

ECOM

ChannelAdvisor

$12.95

-0.15 (-1.15%)

07:20
08/21/18
08/21
07:20
08/21/18
07:20
Conference/Events
ChannelAdvisor management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 23

    Aug

  • 28

    Aug

  • 06

    Sep

  • 07

    Sep

JCI

Johnson Controls

$38.73

0.48 (1.25%)

07:20
08/21/18
08/21
07:20
08/21/18
07:20
Upgrade
Johnson Controls rating change  »

Johnson Controls upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$114.62

-0.13 (-0.11%)

07:19
08/21/18
08/21
07:19
08/21/18
07:19
Periodicals
JPMorgan to launch new investing app for free, CNBC reports »

JPMorgan has plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

  • 26

    Feb

DLB

Dolby

$68.32

-0.75 (-1.09%)

07:19
08/21/18
08/21
07:19
08/21/18
07:19
Conference/Events
Dolby management to meet with William Blair »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 28

    Aug

  • 06

    Sep

EPAM

Epam Systems

$136.36

1.355 (1.00%)

07:18
08/21/18
08/21
07:18
08/21/18
07:18
Recommendations
Epam Systems analyst commentary  »

Epam Systems price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRZO

Carrizo Oil & Gas

$22.79

0.05 (0.22%)

07:17
08/21/18
08/21
07:17
08/21/18
07:17
Conference/Events
Carrizo Oil & Gas management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

BBY

Best Buy

$79.39

0.91 (1.16%)

, AMZN

Amazon.com

$1,875.45

-6.49 (-0.34%)

07:17
08/21/18
08/21
07:17
08/21/18
07:17
Recommendations
Best Buy, Amazon.com analyst commentary  »

Best Buy valuation…

BBY

Best Buy

$79.39

0.91 (1.16%)

AMZN

Amazon.com

$1,875.45

-6.49 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 13

    Sep

ACRS

Aclaris Therapeutics

$16.01

0.34 (2.17%)

07:17
08/21/18
08/21
07:17
08/21/18
07:17
Hot Stocks
Aclaris Therapeutics announces ATI-450 findings in publication »

Aclaris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USB

U.S. Bancorp

$53.81

0.51 (0.96%)

07:17
08/21/18
08/21
07:17
08/21/18
07:17
Recommendations
U.S. Bancorp analyst commentary  »

U.S. Bancorp capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRON

Cronos Group

$7.33

0.78 (11.91%)

07:16
08/21/18
08/21
07:16
08/21/18
07:16
Hot Stocks
Cronos Group announces initial supply agreement for retail distribution »

Cronos Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOME

At Home Group

$34.01

0.06 (0.18%)

07:15
08/21/18
08/21
07:15
08/21/18
07:15
Recommendations
At Home Group analyst commentary  »

At Home Group's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

AZPN

Aspen Technology

$107.56

-0.21 (-0.19%)

07:15
08/21/18
08/21
07:15
08/21/18
07:15
Recommendations
Aspen Technology analyst commentary  »

Aspen Technology price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:15
08/21/18
08/21
07:15
08/21/18
07:15
General news
Treasury Market Outlook: Treasury yields are higher »

Treasury Market Outlook:…

NEO

NeoGenomics

$12.85

0.165 (1.30%)

07:15
08/21/18
08/21
07:15
08/21/18
07:15
Initiation
NeoGenomics initiated  »

NeoGenomics initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.